Related Experiment Video
Updated: Mar 27, 2026

Synthesis of Graphene-Hydroxyapatite Nanocomposites for Potential Use in Bone Tissue Engineering
Published on: July 27, 2022
Poly(L-lactic acid)/poly(3-hydroxybutyrate-co-3-hydroxyhexanoate)/hydroxyapatite based composites for bone tissue
Parul Shukla1, Amrit Pritam Rout1, Arnab Banerjee2
1Centre for Sustainable Polymers, Indian Institute of Technology Guwahati, Assam, 781039, India.
None:
Bone tissue engineering based on injection molded constructs is inherently complex process as the developed material needs to fulfil a whole gamut of criteria to promote cell attachment, proliferation, and differentiation while exhibiting optimum biocompatibility, adequate mechanical stability, and bioresorbability. This study aims to examine the role of Poly (L-Lactic acid) (PLA) and Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx) as melt extruded blends with enhanced properties through addition of bioactive hydroxyapatite (Ca10 (PO4)6(OH)2, (HAp)). The fabricated composites were subjected to impact strength evaluation which indicated reduction in mechanical strength with increasing biofiller content (3, 5, 7, and 10 w/w%). 3 wt% PLA/PHBHHx_HAp was identified optimum with an impact strength of (123.8-476.1 J/m). The in vitro bioactivity evaluation in simulated body fluid (SBF) revealed the complete coverage of PLA/PHBHHx_HAp composites by a thick bone-like apatite layer. The in vitro hydrolytic degradation study (after 60days at 37 °C) of composites exhibited mass loss of about 4.1-5.6%, reflecting slow and gradual degradation behaviour under physiological conditions. Considering porosity and surface characteristics, composite composed of higher PHBHHx content demonstrated higher in vitro cytocompatibility, adhesion, and viability (12-16% increase in 24 h) for MG-63 osteoblast while exhibiting induced calcium deposition and mineralized nodules. This study presents PLA/PHBHHx_HAp biocomposites as promising mechanically tuned biomaterials with demonstrated bioactivity potential and cytocompatibility for potential treatment of osseous defects.

